Medifast (MED) Gains from Sales and Divestitures (2012 - 2021)

Medifast has reported Gains from Sales and Divestitures for 7 years, with the latest figure at $26000.0 in Q3 2021.

• For the quarter ending Q3 2021, Gains from Sales and Divestitures fell 13.33% year-over-year to $26000.0; the trailing twelve-month figure through Sep 2021 stood at $26000.0 (down 13.33% YoY), and the FY2020 full-year result was $32000.0, down 13.51% from the prior year.
• Gains from Sales and Divestitures for Q3 2021 stood at $26000.0, up from $25000.0 in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $210000.0 in Q1 2018, with the low at $14000.0 in Q1 2021.
• Historically, Gains from Sales and Divestitures has averaged $53505.3 across 5 years, with a median of $32000.0 in 2019.
• Annual changes were most pronounced in 2018 — Gains from Sales and Divestitures surged 281.82% — and 2019, when it plunged 90.0%.
• Medifast's Gains from Sales and Divestitures stood at $120000.0 in 2017, then slipped by 24.17% to $91000.0 in 2018, then tumbled by 59.34% to $37000.0 in 2019, then retreated by 13.51% to $32000.0 in 2020, then fell by 18.75% to $26000.0 in 2021.
• The last three Gains from Sales and Divestitures figures came in at $26000.0 (Q3 2021), $25000.0 (Q2 2021), and $14000.0 (Q1 2021), per Business Quant data.